Edition:
United States

Genomic Health Inc (GHDX.O)

GHDX.O on Nasdaq

29.25USD
22 Nov 2017
Change (% chg)

$-0.09 (-0.31%)
Prev Close
$29.34
Open
$29.24
Day's High
$29.64
Day's Low
$28.82
Volume
62,960
Avg. Vol
113,438
52-wk High
$34.02
52-wk Low
$26.37

Chart for

About

Genomic Health, Inc. is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company's Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression... (more)

Overall

Beta: 0.70
Market Cap(Mil.): $1,020.60
Shares Outstanding(Mil.): 34.79
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 200.71 15.46
EPS (TTM): -- -- --
ROI: -- -10.20 11.85
ROE: -- -36.19 15.83

BRIEF-Genomic Health Q3 loss per share $0.06

* Genomic Health announces third quarter 2017 financial results and reports recent business progress

Nov 08 2017

BRIEF-Genomic Health and Biocartis announce agreement to develop a breast cancer test

* ‍GENOMIC HEALTH AND BIOCARTIS ANNOUNCE AGREEMENT TO DEVELOP AN IDYLLA(TM) IVD ONCOTYPE DX(®) BREAST CANCER TEST TO BROADEN GLOBAL PATIENT ACCESS​

Sep 13 2017

BRIEF-Palmetto GBA issues positive final local coverage determination to expand medicare coverage of Oncotype DX genomic prostate score test

* Palmetto GBA issued positive final local coverage determination to expand medicare coverage of Oncotype DX genomic prostate score test Source text for Eikon: Further company coverage:

Aug 24 2017

BRIEF-Genomic Health Q2 loss per share $0.08

* Genomic Health announces second quarter 2017 financial results and reports recent business progress

Aug 01 2017

Earnings vs. Estimates